Acta Biomedica Scientia

TO STUDY THERAPEUTIC USE OF TERIPARATIDE WITH FRACTURES THAT DELAY HEALING OF THE LOWER LIMBS: UPDATE

Thulasi Ram Chebolu, Bhaskar Reddy Surapu

drpebyreddy@gmail.com

Teriparatide, Parathyroid Hormone, Radiological union, strontium ranelate

According to the Food and Drug Administration (FDA), a fracture is considered persistent if it lasts for at least nine months without showing any indications of healing for three months. The biggest difficulty now facing orthopedic surgeons is delayed bone healing and nonunion. The failure of the body to mend a fracture is known as nonunion of bone. The aim of the study was to Therapeutic use of teriparatide with fractures that delay healing of the lower limbs: update The current prospective interventional study was carried out on patients attending our tertiary care Sri Lakshmi Narayana Institute of Medical Sciences, Pondicherry, Orthopaedic Emergency and Outpatient Department over a one-year period.A total of 160 patients were initially enrolled and then after meeting inclusion criteria total 124 patients were selected for study. They were divided by randomisation by 1:1 method into two groups- Group A was test group of 62 cases; in which subcutaneous injection TPH 20 mcg daily up to six months was given along with calcium 500 mg and vitamin D 25 mcg, while in 62 cases in Group B (control group) only calcium 500 mg and vitamin D 25 mcg were given. Injection TPH was started within 10 days of fracture and given for six months. No placebo injection was given in control group. A 42 (67%) cases presented within 24 hours of injury, 32 (52%) cases reported between 24 to 48hours and 30 (48%) cases came after 48 hours of injury. All patients in test group were started with TPH within 10 days of fracture. A 38/62 (61.2%) cases of test group while 37/62 (60%) cases of control group were treated by surgical methods by open reduction and internal fixation by interlocking nailing (42/85; 49%) and plating (33/85; 39%). All those 85 patients 2 needing surgery in both test and control groups were operated within 2 to 7 days of presentation. TPH 20 mcg subcutaneously administered daily for six months at a regular dose may accelerate clinical and radiographic fracture union, encourage early weight bearing, and improve the alleviation of pain. As a result, improved functional outcomes and pre-fracture ambulatory status are possible without experiencing any serious side effects